January 9, 2019 / 6:20 AM / 14 days ago

BRIEF-Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib

Jan 9 (Reuters) - Basilea Pharmaceutica AG:

* BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA)

* 21% OBJECTIVE RESPONSE RATE WITH SIX CONFIRMED PARTIAL RESPONSES FROM 29 EVALUABLE PATIENTS

* 83% DISEASE CONTROL RATE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below